<<NavDx Reference List>>
Our Mission.
Naveris® is committed to transforming outcomes for patients with HPV-associated cancers through precision liquid biopsy. Our goal is to give clinicians earlier, more reliable answers—so patients receive the care they need, when they need it.
About Naveris.
Naveris Inc., founded in 2017, is a molecular diagnostics company developing and commercializing novel liquid biopsies to enhance the early detection and clinical management of viral-associated cancers. Our highly sensitive tests use our disruptive proprietary technology to capture and analyze cancer-associated DNA in blood plasma and offer greater sensitivity compared to existing circulating tumor DNA (ctDNA) tests.
Our flagship clinically available product is the NavDx® test—the first and most clinically validated, highly sensitive blood test for HPV+ cancers. The NavDx test is a purpose-built, proprietary ddPCR assay designed specifically for the unique biology of viral cancers. The test enables earlier detection of cancer recurrence in patients in remission, especially those who are asymptomatic at the time of testing, as well as real-time monitoring of response in patients undergoing treatment, and confirmatory diagnosis in patients for whom imaging or traditional biopsies are inconclusive or unsuitable. The NavDx test has established its ability to monitor patients for HPV+ head & neck1,2,3 and anal cancer4,5 recurrence, with over 47 peer-reviewed publications from 44 unique studies and more than 120,000+ tests performed.
HPV-driven cancers present a surveillance challenge that existing tools have not fully solved. Despite generally favorable prognoses, 15–25% of HPV+ oropharyngeal cancer patients and 20–30% of HPV+ anal cancer patients experience recurrence within 5 years of completing treatment.11,12
Standard-of-care surveillance methods, like clinical exams, scopes, and imaging, often lack the sensitivity to catch recurrence before it becomes clinically apparent. Most recurrences are first reported by the patient, not caught proactively at a scheduled visit.11 By the time disease is clinically apparent, the window for optimal salvage intervention may have narrowed significantly.
NavDx was designed to close this gap by providing a highly sensitive, blood-based molecular signal that can detect recurrence before symptoms appear and before imaging turns positive.
Our Solution.
Conventional circulating tumor DNA (ctDNA) tests look for somatic mutations in human DNA shed by tumor cells. This approach works across many cancer types but faces an inherent challenge: Because mutated DNA fragments are rare against the vast volume of the patient’s normal DNA, sensitivity is limited when tumor burden is low, precisely the stage at which early detection matters most.
The NavDx test takes a fundamentally different approach. Tumor tissue modified viral HPV DNA (TTMV-HPV DNA) is present exclusively in HPV-driven tumor cells, not in normal tissue. Because it is of viral origin, its presence cannot be mistaken for or conflated with the patient’s own human DNA, which is why the NavDx test can achieve ≥97% specificity in HPV+ oropharyngeal cancer and ≥98.4% specificity in HPV+ anal cancer even when disease burden is very low.
Looking Ahead.
Naveris is actively evaluating the application of TTMV liquid biopsy to HPV+ cervical cancer, where early clinical data are encouraging.